Atopic Dermatitis

Investigators reported that a higher proportion of participants in the abatacept group relapsed between weeks 12 and 40 compared to participants in the ustekinumab group.

Investigators recommended a treatment course of at least 1-2 months with medium strength to potent topical corticosteroids should be considered before dupilumab discontinuation in affected children and adolescents.

Though high-dose ultraviolet therapy was also effective, investigators were concerned with the potential long-term adverse events.

This represents the first biologic to show positive phase 3 results in prurigo nodularis.

The panelists discuss real-world use of topical ruxolitinib in atopic dermatitis management given safety, efficacy, and availability.

Considerations for topical ruxolitinib with deference to positive clinical trial results in atopic dermatitis.

The risk of developing atopic dermatitis due to these combined effects is especially prevalent in infant boys with high maternal anxiety.

Patients treated with the monoclonal antibody had increased incidences of conjunctivitis, though many of these incidences were considered mild and were resolved by the end of the study.

Shared insight on the available JAK inhibitors for atopic dermatitis, both topical and systemic.

Experts reflect on the various comorbid conditions associated with atopic dermatitis and how they can affect patients.

Investigators collected data from several studies which tested the efficacy of the ointment on pediatric populations affected by atopic dermatitis and their families.

Investigators reported that machine learning was non-invasive and accessible to a large array of clinicians, and could help prevent infants from developing atopic dermatitis.

Investigators believe that pediatric patients can gain the most from a combination of interventions, though larger studies are needed to confirm the data.

Dr. Hawryluk speaks of improving upon tolerability of existing therapies for atopic disease as well as promising new therapies on the horizon.

Dr. De Keyser highlights the success of biologics such as omalizumab and dupilumab in the treatment of asthma and atopic dermatitis in pediatric populations.

Investigators believe the reduction of DIF usage could result in cost reductions without compromising patient care.

Comprehensive discussion on how atopic dermatitis can impact a patient’s quality of life.

Considerations for persistent atopic dermatitis vs outgrowing disease, followed by triggers that can result in flare-ups.

Delgocitinib is the first and only topical JAK/STAT pathway inhibitor in Japan, and recent data suggests it is effective in the management of atopic dermatitis.

Dr. Paller speaks of the AD-GAP study, which shared insights on moderate to severe atopic dermatitis from patients, caregivers, and independent physicians.

Adult patients with moderate-to-severe atopic dermatitis reported incremental improvement of their condition in a new extension trial study presented at EADV.

Shared insight on the ways a child or adult may present with atopic dermatitis.

A panel of experts review the pathophysiology of atopic dermatitis and its contributing factors.

Additionally, investigators believe epidermal impairment in the skin of children with atopic dermatitis could contribute to the development of allergic sensitization.

Acknowledging the potential medical harm from errors and bias, investigators believe clinical AI needs to be held to a higher standard.